Coronavirus envelope protein activates TMED10-mediated unconventional secretion of inflammatory factors.

Coronavirus envelope protein activates TMED10-mediated unconventional secretion of inflammatory factors.

Publication date: Oct 08, 2024

The precise cellular mechanisms underlying heightened proinflammatory cytokine production during coronavirus infection remain incompletely understood. Here we identify the envelope (E) protein in severe coronaviruses (SARS-CoV-2, SARS, or MERS) as a potent inducer of interleukin-1 release, intensifying lung inflammation through the activation of TMED10-mediated unconventional protein secretion (UcPS). In contrast, the E protein of mild coronaviruses (229E, HKU1, or OC43) demonstrates a less pronounced effect. The E protein of severe coronaviruses contains an SS/DS motif, which is not present in milder strains and facilitates interaction with TMED10. This interaction enhances TMED10-oligomerization, facilitating UcPS cargo translocation into the ER-Golgi intermediate compartment (ERGIC)-a pivotal step in interleukin-1 UcPS. Progesterone analogues were identified as compounds inhibiting E-enhanced release of proinflammatory factors and lung inflammation in a Mouse Hepatitis Virus (MHV) infection model. These findings elucidate a molecular mechanism driving coronavirus-induced hyperinflammation, proposing the E-TMED10 interaction as a potential therapeutic target to counteract the adverse effects of coronavirus-induced inflammation.

Open Access PDF

Concepts Keywords
Coronaviruses Animals
Driving Coronavirus Envelope Proteins
Inflammation Coronavirus Envelope Proteins
Mild Coronavirus Infections
Tmed10 COVID-19
Golgi Apparatus
HEK293 Cells
Humans
Inflammation
Lung
Mice
Murine hepatitis virus
SARS-CoV-2

Semantics

Type Source Name
disease IDO protein
disease MESH coronavirus infection
pathway REACTOME Release
disease MESH lung inflammation
drug DRUGBANK Progesterone
disease MESH infection
disease MESH inflammation
disease MESH Hepatitis
disease MESH lung injuries
disease IDO process
disease MESH multiple organ dysfunction syndrome
pathway REACTOME Immune System
disease MESH bacterial infection
pathway REACTOME Autophagy
drug DRUGBANK Esomeprazole
disease IDO host
disease IDO site
drug DRUGBANK Coenzyme M
drug DRUGBANK Myricetin
disease MESH SARS CoV 2 infection
pathway REACTOME Pyroptosis
pathway REACTOME Inflammasomes
disease MESH death
disease IDO symptom
disease IDO production
drug DRUGBANK Albendazole
drug DRUGBANK Dimethyl sulfoxide
disease IDO assay

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *